Abstract
Monoclonal antibody (MAB) infusions were approved under an emergency use authorization for treatment of mild to moderate COVID-19 infection in adults and pediatric patients who are at high risk for progressing to severe COVID-19 and/or hospitalization. Obstetric patients infected with COVID-19 are at increased risk for developing severe illness and death compared with nonpregnant adults. Pregnancy-specific data on the use of Anti-SARS-CoV-2 MABs are needed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Obstetric, Gynecologic & Neonatal Nursing
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
